bluebird bio, Inc. (BLUE) News
Filter BLUE News Items
BLUE News Results
|Loading, please wait...|
BLUE News Highlights
- For BLUE, its 30 day story count is now at 10.
- Over the past 15 days, the trend for BLUE's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- BIO, GENE and AGE are the most mentioned tickers in articles about BLUE.
Latest BLUE News From Around the Web
Below are the latest news stories about bluebird bio Inc that investors may wish to consider to help them evaluate BLUE as an investment opportunity.
bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the first quarter ended March 31, 2021 and shared recent operational progress.
In this episode of Rule Breaker Investing, we review 5 Stocks for the Coronavirus, 5 Stocks for the Age of Miracles, and 5 Stocks I Own That You Should, Too. To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. David Gardner: Last April, the market was in as dark a place as any of us have seen for more than 10 years -- the 35% loss of the S&P 500 in 32 days.
Bluebird (BLUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the following upcoming investor conferences:
Bristol Myers Squibb (NYSE: BMY) and bluebird bio (NASDAQ: BLUE) recently gained Food and Drug Administration approval of Abecma. In this video from Motley Fool Live, recorded on March 29, Fool.com Contributors Brian Orelli and Keith Speights discuss the prospects for Abecma and what the companies are doing to increase the potential market for the chimeric antigen receptor T-cell (CAR-T) product. Brian Orelli: On Friday, the FDA approved Bristol Myers Squibb and Bluebird Bio's CAR-T treatment for multiple myeloma.
Last week, Vertex Pharmaceuticals (NASDAQ: VRTX) announced that it would pay CRISPR Therapeutics (NASDAQ: CRSP) a whopping $900 million to take more control of the duo's gene therapy collaboration, CTX001. CTX001 is being investigated as a potentially curative treatment for severe sickle cell disease and beta thalassemia, a rare blood disorder. Beti-cel is already on the market in the EU for beta thalassemia, but Bluebird is still facing a slew of problems in the U.S. and in major European markets.
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
bluebird bio, Inc. ( NASDAQ:BLUE ) shareholders will have a reason to smile today, with the analysts making substantial...
The decision by bluebird bio ([[BLUE]] +0.1%) to withdraw Zynteglo (betibeglogene autotemcel) for transfusion-dependent β-thalassemia (“TDT”) from the German market did not come as a surprise.A Suspected Unexpected Serious Adverse Reaction (SUSAR) of acute myeloid leukemia (AML) forced a temporary suspension of two clinical trials in sickle cell disease for its...
bluebird bio, Inc. (Nasdaq: BLUE) announced today business and program updates across its severe genetic disease portfolio including a revised diagnosis for the previously reported case of myelodysplastic syndrome (MDS) in its Phase 1/2 study of LentiGlobin for sickle cell disease (SCD) (bb1111), the company’s decision to withdraw ZYNTEGLO™ (betibeglogene autotemcel, beti-cel) for transfusion-dependent β-thalassemia (TDT) from the German market and a targeted reshaping of its workforce intended to enable the company to advance its late-stage gene therapy programs.